Literature DB >> 16467657

Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection.

Susan C Fagan1, Anna Kozak, William D Hill, David M Pollock, Lin Xu, Maribeth H Johnson, Adviye Ergul, David C Hess.   

Abstract

BACKGROUND: After ischemic stroke, hypertension increases the risk of recurrence, hemorrhage and fatal cerebral edema, but blood pressure (BP) lowering in the acute stroke period is controversial due to fears of infarct extension and worsened outcomes.
OBJECTIVE: To determine whether BP lowering with candesartan, initiated at reperfusion, can reduce neurovascular damage and improve outcome in a model of hypertension after experimental ischemic stroke.
METHODS: Male Wistar rats (280-305 g) underwent 3 h of middle cerebral artery occlusion (MCAO). At reperfusion, either saline (n = 18) or candesartan 1 mg/kg (n = 18) was administered intravenously. BP was measured by telemetry for 2 days before and 24 h after MCAO. Neurologic function was assessed and sacrifice occurred at 24 h after occlusion. Brain tissue was analyzed for infarct size, hemoglobin content and edema.
RESULTS: Mean BP increased from 96 to 124 mmHg immediately upon MCAO and decreased to 114 mmHg after reperfusion, remaining elevated for 24 h (P < 0.001) in the saline group. Candesartan reduced BP back to baseline and BP remained lower than in saline-treated animals until sacrifice (P < 0.001). Infarct size (54 versus 38%, P = 0.01) and hemoglobin content (23.4 versus 10.0 microg/g tissue; P = 0.03) and edema (17.97 versus 11.33%, P < 0.0001) were lower in the candesartan group. In addition, neurologic function at 24 h was improved (P = 0.0036) in the candesartan group.
CONCLUSIONS: Candesartan administered after reperfusion in acute ischemic stroke reduces neurovascular damage and improves outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467657     DOI: 10.1097/01.hjh.0000209990.41304.43

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  22 in total

1.  Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury.

Authors:  Abdelrahman Y Fouda; Bindu Pillai; Krishnan M Dhandapani; Adviye Ergul; Susan C Fagan
Journal:  Eur J Pharmacol       Date:  2017-02-10       Impact factor: 4.432

2.  Drug repurposing for vascular protection after acute ischemic stroke.

Authors:  Weihua Guan; Anna Kozak; Susan C Fagan
Journal:  Acta Neurochir Suppl       Date:  2011

3.  Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?

Authors:  Juraj Culman; Toni Jacob; Sven O Schuster; Kjell Brolund-Spaether; Leonie Brolund; Ingolf Cascorbi; Yi Zhao; Peter Gohlke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-02       Impact factor: 3.000

4.  Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke.

Authors:  Abdelrahman Y Fouda; Ahmed Alhusban; Tauheed Ishrat; Bindu Pillai; Wael Eldahshan; Jennifer L Waller; Adviye Ergul; Susan C Fagan
Journal:  Mol Neurobiol       Date:  2016-01-12       Impact factor: 5.590

5.  Use of renin-angiotensin system blockade in patients with renal artery stenosis.

Authors:  Jordana B Cohen; Raymond R Townsend
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 8.237

6.  Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow.

Authors:  Sigurdur T Sigurdsson; Olaf B Paulson; Arne Høj Nielsen; Svend Strandgaard
Journal:  J Cereb Blood Flow Metab       Date:  2013-12-11       Impact factor: 6.200

Review 7.  Drug therapy for the secondary prevention of stroke in hypertensive patients: current issues and options.

Authors:  Stephan Lüders
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke.

Authors:  Tauheed Ishrat; Bindu Pillai; Adviye Ergul; Sherif Hafez; Susan C Fagan
Journal:  Neurochem Res       Date:  2013-11-06       Impact factor: 3.996

9.  AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.

Authors:  Ahmed Alhusban; Anna Kozak; Adviye Ergul; Susan C Fagan
Journal:  J Pharmacol Exp Ther       Date:  2012-12-04       Impact factor: 4.030

10.  Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke.

Authors:  Anna Kozak; Adviye Ergul; Azza B El-Remessy; Maribeth H Johnson; Livia S Machado; Hazem F Elewa; Mohammed Abdelsaid; Daniel C Wiley; Susan C Fagan
Journal:  Stroke       Date:  2009-03-05       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.